Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Government extends...

    Government extends deadline to impose high import duties on 29 US products till May 2

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-04-01T10:00:32+05:30  |  Updated On 1 April 2019 10:00 AM IST
    Government extends deadline to impose high import duties on 29 US products till May 2
    The government has extended this deadline over half a dozen times since June 2018, when it decided to impose these duties in retaliation to a move by the US to impose high customs duties on certain steel and aluminium products.


    New Delhi: The government has again extended its deadline to impose retaliatory customs duties on 29 US products, including almond, walnut and pulses, till May 2. A notification of the finance ministry said that implementation of increased customs duty on specified imports originating in the US has been postponed from April 1, 2019, to May 2, this year.



    The government has extended this deadline over half a dozen times since June 2018, when it decided to impose these duties in retaliation to a move by the US to impose high customs duties on certain steel and aluminium products.

    India is pushing the dates as both sides are negotiating a trade package to boost bilateral commerce. But earlier this month, the US decided to withdraw export incentives being provided by them to Indian exporters for certain goods under Generalised System of Preferences (GSP) programme.

    Extension of these benefits were part of the negotiations between India and the US among other issues. These incentives are expected to be withdrawn from May 2. Domestic exporters are jittery over US' decision to withdraw these incentives as they export goods worth USD 5.6 billion under GSP programme. About 1,900 items including from chemicals and engineering sectors avail these sops.

    The government is considering to send a delegation to the US earlier next month to hold discussions on ways to resolve all trade-related issues.

    Both sides were holding two-track discussions to increase trade in short and medium term, and identify long-term trade potentials.

    India is pressing for exemption from high duty imposed by the US on certain steel and aluminium products, resumption of export benefits to certain domestic products under their GSP programme, greater market access for its products from agriculture, automobile, automobile components and engineering sectors.

    On the other hand, the US is demanding greater market access through cut in import duties for its agriculture goods, dairy products, medical devices, IT and communication items. India has stated that it would be difficult for them to cut duties on IT products.

    As part of the imposition of higher import duties, New Delhi has notified higher tariffs on several products. While import duty on walnut has been hiked to 120 per cent from 30 per cent currently, duty on chickpeas, Bengal gram (chana) and masur dal will be raised to 70 per cent, from 30 per cent currently. Levy on lentils will be increased to 40 per cent, from 30 per cent.

    India's exports to the US in 2017-18 stood at USD 47.9 billion, while imports were USD 26.7 billion. The trade balance is in favour of India.

    Also Read: China removes import duties on 28 medicines; India to get boost

    almondaluminium productsboost bilateralchickpeasdomestic productsGeneralised System of PreferencesgovernmentGSP programmehealthHealthcarehigh import dutiesimport dutiesIndian exportersIT productslatest policy newsNew Delhipulseswalnut
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok